BETTA PHARMACEUTICALS: The Macao Drug Regulatory Authority has approved the marketing of Enasidenib Hydrochloride Capsules
I'm LongbridgeAI, I can summarize articles.BETTA PHARMACEUTICALS recently received approval from the Macao Drug Administration for the official launch of ensartinib hydrochloride capsules (brand name: Baimena®). This medication is indicated for the treatment of patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Ensartinib is a novel ALK inhibitor jointly developed by BETTA PHARMACEUTICALS and its subsidiary Xcovery
According to the Zhitong Finance APP, BETTA PHARMACEUTICALS (300558.SZ) announced that recently, the official website of the Drug Administration of the Macao Special Administrative Region of the People's Republic of China (hereinafter referred to as "ISAF") publicized that ISAF has approved the listing of the hydrochloride ensartinib capsules (trade name: Baimena®, hereinafter referred to as "ensartinib") submitted by the company. The approved indication is: this product is indicated as a monotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are positive for anaplastic lymphoma kinase (ALK).
It is reported that ensartinib is a new generation of ALK inhibitor that is highly effective and highly selective, developed as an independent innovative drug by the company and its holding subsidiary Xcovery Holdings, Inc. (hereinafter referred to as "Xcovery").
As of the date of this announcement, the ALK inhibitors that have been listed in Macao include: crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib